Skip to main content

Table 2 Engraftment and GVHD

From: Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party

  No-ATG ATG p value
Total number of patients 421 145  
Engraftment, n (%) 411 (98.6%) 145 (100%) 0.15
 No engraftment, n (%) 6 (1.4%) 0 (0%)
 Missing, n 5 0
Median time ANC > 0.5 G/L (days, range) 15 (5–45) 14 (5–28) 0.001
Acute GVHD,
 Grade 0–I, n (%) 315 (78.2%) 116 (84.7%) 0.10
 Grade II–IV, n (%) 88 (21.8%) 21 (15.3%)
 Grade III–IV, n (%) 31 (7.7%) 6 (4.4%) 0.19
 Missing, n 5 3
Chronic GVHDa
 All grades 52% (46–57.7) 30.8% (22.3–39.8) 0.00026
 Extensive 26.3% (21.2–31.6) 7.6% (3.5–13.7) 4.7 × 10−5
 Limited, n 71 26  
 Extensive; n 77 8
 Missing, n 117 28
  1. ATG anti-thymocyte globulin, GVHD graft-versus-host disease
  2. aTwo-year cumulative incidence